Pam Bondi Fired — What It Means for Cannabis
The New York Times reported that Pam Bondi was potentially on her way out as Attorney General under Donald Trump. Fast forward to Thursday, and now multiple outlets are reporting that Pam Bondi has in fact been fired—with Lee Zeldin being considered as a possible replacement. So what does that mean for cannabis rescheduling? That’s exactly where we start on this episode of Trade To Black, presented by Flowhub, with Marc Cohodes weighing in. Then Adam Stettner from FundCanna joins us once again to break down a controversial move where Idaho lawmakers are urging voters not to even sign a petition for medical cannabis.
Analyst Marc Cohodes opened the program with a bullish take on the hemp industry, pointing to a newly launched Medicare CBD/THCA pilot program as evidence that federal momentum is building. He argued that the Farm Bill’s hemp provisions will be extended rather than allowed to expire, with the expected framework including a ban on synthetic cannabinoids, FDA warning labels, and a federal excise tax he estimated at around five percent — consistent, he noted, with how cannabis itself is likely to be taxed under Schedule 3. Shadd Dales and Anthony Varrell break down how this leadership shake-up could impact timing, decision-making, and overall momentum around federal cannabis reform—especially with the industry already watching closely for movement.
On rescheduling itself, despite that Pam Bondi’s been fired, both Cohodes and FundCanna CEO Adam Stettner expressed confidence that it will happen, urging investors to stop fixating on timing and instead focus on which companies are best positioned to capitalize.
In Idaho, the state Senate passed a resolution urging residents not to sign a medical marijuana ballot petition — despite polls showing 83 percent of Idahoans support some form of legalization. Stettner called the move deeply contradictory for lawmakers who present themselves as champions of small government and the will of the people. This goes beyond cannabis—it’s about control, voter rights, and whether government is stepping in where it shouldn’t. With medical cannabis already established across most of the U.S., the bigger question becomes: why block the process instead of letting voters decide?
This episode connects the dots between federal policy shifts and state-level resistance—something every investor and operator needs to understand right now.
